Propanc Biopharma, Inc.

PPCB

US74346N6022

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:58:41 2024-05-31 EDT			5-day change	1st Jan Change
0.0019 ^USD	-.--%		+72.73%	-84.17%

05-15	Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
04-16	Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	CI

Propanc Biopharma, Inc. announced that it has received $0.065 million in funding

July 05, 2023

On July 6, 2023, Propanc Biopharma, Inc. closed the transaction. The company has received $65,000 from 1 investor pursuant to Regulation D.

Latest news about Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-15	CI
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	04-16	CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	04-15	CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	02-29	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-20	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	01-16	CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	12-10	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	12-03	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	23-10-28	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	23-10-19	CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	23-10-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	23-10-11	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	23-08-30	CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding	23-08-29	CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC	23-08-22	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding	23-08-15	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	23-08-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.12 million in funding	23-08-14	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	23-08-14	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.045 million in funding	23-07-18	CI
Propanc Biopharma, Inc. and an Institutional Investor Enters into a Loan Agreement	23-07-12	CI
Propanc Biopharma, Inc. announced that it has received $0.065 million in funding	23-07-05	CI
Propanc Biopharma, Inc. Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors	23-07-05	CI

Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROPANC BIOPHARMA, INC.	-84.17%	319K
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B